22 / 29
Page 58
Volume 9
Journal of Obesity & Weight Loss Therapy
ISSN: 2165-7904
JOINT EVENT
Childhood Obesity 2019
Diabetes Conference 2019
March 18-19, 2019
&
3
rd
World Congress on
Diabetes and Obesity
12
th
International Conferences on
Childhood Obesity and Nutrition
March 18-19, 2019 | Rome, Italy
Prevalence of Diabetic Nephropathy and associated Risk Factors among Type 2 Diabetes Mellitus Patients
in Ramallah, Palestine
Moyad Jamal Shahwan
Ajman University, UAE
Aim:
Albuminuria is an established marker for endothelial dysfunction and cardiovascular risk in diabetes and pre-
diabetes. So we aimed to explore the prevalence of albuminuria (micro-albuminuria and macro-albuminuria) in
patients with type2 diabetes mellitus (DM) in the Palestinian community and to determine the association between
albuminuria and other health care and biochemical indicators.
Methods:
A cross-sectional study was carried out at private health care center. A total of 550 diabetic patients aged
35 years and above with type 2 diabetes mellitus who attended the clinic from May 2017 through February 2018
were included. Socio-demographic, clinical, and laboratory data were obtained from the medical records of patients.
Statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS, version 23).
Results:
Out of the 550 patients recruited, the mean age and duration of diabetes were 57.8 years and 9.5 years,
respectively. Approximately 62% were being managed by oral hypoglycemic agents alone, 4.3% by insulin alone,
31.7% were on a combination of oral hypoglycemic agents and insulin and slightly less than 2% were on dietary
measures alone. The mean value for HbA1c was 7.71%. The overall prevalence of albuminuria among participants
was found to be 34.6%; micro-albuminuria (29.3%) and macro-albuminuria (5.3%).
Conclusions:
Albuminuria is highly prevalent among Palestinian population with type 2 diabetes. This calls for early
and universal screening of urinary albumin. There is also an urgent need for measures that target tight glycemic and
optimal blood pressure control and the use of renin-angiotensin system blockade.
J Obes Weight Loss Ther 2019, Volume 9
DOI: 10.4172/2165-7904-C1-091